MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2008.05.059

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2008

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

King Christopher R, Brooks James D, Gill Harcharan, Pawlicki Todd, Cotrutz Cristian, Presti Joseph C

Клиническое исследование II фазыСтатьяПеревод в очереди

Аннотация

PURPOSE: The radiobiology of prostate cancer favors a hypofractionated dose regimen. We report results of a prospective Phase II clinical trial of stereotactic body radiotherapy (SBRT) for localized prostate cancer.

METHODS AND MATERIALS: Forty-one low-risk prostate cancer patients with 6 months' minimum follow-up received 36.25 Gy in five fractions of 7.25 Gy with image-guided SBRT alone using the CyberKnife. The early (<3 months) and late (>6 months) urinary and rectal toxicities were assessed using validated quality of life questionnaires (International Prostate Symptom Score, Expanded Prostate Cancer Index Composite) and the Radiation Therapy Oncology Group (RTOG) toxicity criteria. Patterns of prostate-specific antigen (PSA) response are analyzed.

RESULTS

The median follow-up was 33 months. There were no RTOG Grade 4 acute or late rectal/urinary complications. There were 2 patients with RTOG Grade 3 late urinary toxicity and none with RTOG Grade 3 rectal complications. A reduced rate of severe rectal toxicities was observed with every-other-day vs. 5 consecutive days treatment regimen (0% vs. 38%, p = 0.0035). A benign PSA bounce (median, 0.4 ng/mL) was observed in 12 patients (29%) occurring at 18 months (median) after treatment. At last follow-up, no patient has had a PSA failure regardless of biochemical failure definition. Of 32 patients with 12 months minimum follow-up, 25 patients (78%) achieved a PSA nadir </=0.4 ng/mL. A PSA decline to progressively lower nadirs up to 3 years after treatment was observed.

CONCLUSIONS

The early and late toxicity profile and PSA response for prostate SBRT are highly encouraging. Continued accrual and follow-up will be necessary to confirm durable biochemical control rates and low toxicity profiles.

Для цитирования: King Christopher R, Brooks James D, Gill Harcharan, Pawlicki Todd, Cotrutz Cristian, Presti Joseph C. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.. International journal of radiation oncology, biology, physics. 2008. DOI: 10.1016/j.ijrobp.2008.05.059.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.